Mizuho Reiterates "Buy" Rating for ICON Public (NASDAQ:ICLR)

ICON Public (NASDAQ:ICLR - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Mizuho in a research note issued on Thursday, Benzinga reports. They currently have a $346.00 target price on the medical research company's stock. Mizuho's target price points to a potential upside of 10.48% from the stock's previous close.

Other analysts have also issued reports about the stock. Barclays upped their price objective on shares of ICON Public from $325.00 to $355.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Evercore ISI increased their price target on shares of ICON Public from $325.00 to $350.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd. Citigroup upped their target price on ICON Public from $300.00 to $315.00 and gave the company a "buy" rating in a research report on Monday, December 11th. Truist Financial upped their price objective on shares of ICON Public from $357.00 to $367.00 and gave the stock a "buy" rating in a research report on Friday, February 23rd. Finally, JPMorgan Chase & Co. boosted their target price on shares of ICON Public from $295.00 to $330.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 20th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $319.45.

ICON Public Trading Down 2.5 %

ICLR traded down $7.91 during mid-day trading on Thursday, hitting $313.18. 508,573 shares of the stock were exchanged, compared to its average volume of 565,600. The firm's fifty day moving average is $307.52 and its two-hundred day moving average is $276.25. ICON Public has a 1-year low of $181.92 and a 1-year high of $344.77. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40. The company has a market cap of $25.84 billion, a PE ratio of 43.56, a PEG ratio of 1.52 and a beta of 1.15.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.13. ICON Public had a net margin of 7.54% and a return on equity of 11.42%. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. Equities analysts forecast that ICON Public will post 14.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ICLR. Livelsberger Financial Advisory acquired a new stake in ICON Public during the 4th quarter valued at $29,000. Chartwell Investment Partners LLC raised its position in shares of ICON Public by 23.5% during the 4th quarter. Chartwell Investment Partners LLC now owns 8,589 shares of the medical research company's stock worth $2,431,000 after buying an additional 1,636 shares in the last quarter. LM Advisors LLC acquired a new stake in shares of ICON Public during the fourth quarter worth $26,000. State of Tennessee Treasury Department lifted its position in shares of ICON Public by 4.9% in the fourth quarter. State of Tennessee Treasury Department now owns 155,797 shares of the medical research company's stock worth $44,101,000 after purchasing an additional 7,270 shares in the last quarter. Finally, Crossmark Global Holdings Inc. bought a new stake in shares of ICON Public in the 4th quarter valued at approximately $201,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.